U.S. Dollar Hits Two-Month High as Oil, Treasury Yields Surge 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
RBI Uses $10 Billion Currency Swaps to Drain Excess Rupee Liquidity 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
Judge Orders Trump to Restore White House Access for CNN, MS NOW and Politico 
Brazil Court Suspends Sigma Lithium Mine Operations 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Dollar Holds Near Two-Month High as Yen Approaches 160 
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh 
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
Add as a preferred source on Google
The US Food and Drug Administration (FDA) is planning to regulate the use of the cannabis compound CBD in food and supplements after weighing the evidence on the compound's safety.
The FDA will decide whether regulating legal cannabis will require new agency rules or new legislation from Congress.
Cannabis products, excluding Epidiolex, are illegal at the federal level in the US, although some states allow their use.
According to Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, the FDA will ascertain if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility.
.
